Targeting Jab1/CSN5 in nasopharyngeal carcinoma

Cancer Letters

Volumn 326, Issue 2, 2012, Pages 155-160

  Pan, Yunbao ^a,b   Claret, Francois X ^a,c  

^a UNIVERSITY OF TEXAS   (United States)

^b SUN YAT SEN UNIVERSITY   (China)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

DNA repair; Epstein Barr virus associated malignancy; Jab1 CSN5; Nasopharyngeal carcinoma; P27Kip1; Tumorigenesis

Indexed keywords

CISPLATIN; CONSTITUTIVE PHOTOMORPHOGENIC 9 SIGNALOSOME SUBUNIT 5 PROTEIN; ONCOPROTEIN; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL DESTRUCTION; CANCER GROWTH; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CARCINOGENESIS; CELL CYCLE PROGRESSION; CELL GROWTH; CONSTITUTIVE PHOTOMORPHOGENIC 9 SIGNALOSOME SUBUNIT 5 GENE; DISEASE FREE INTERVAL; DNA DAMAGE; DNA REPAIR; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; NASOPHARYNX CARCINOMA; NONHUMAN; ONCOGENE; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN TARGETING;

APOPTOSIS; CELL CYCLE; CELL PROLIFERATION; CISPLATIN; DISEASE PROGRESSION; DNA DAMAGE; DNA REPAIR; GENE EXPRESSION; GENOMIC INSTABILITY; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NASOPHARYNGEAL NEOPLASMS; PEPTIDE HYDROLASES; PROGNOSIS; SIGNAL TRANSDUCTION;

HUMAN HERPESVIRUS 4;

EID: 84866859568     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.07.033     Document Type: Article

References (70)

1. Lo K.W., Chung G.T., To K.F. Deciphering the molecular genetic basis of NPC through molecular, cytogenetic, and epigenetic approaches. Semin. Cancer Biol. 2012, 22:79-86.
2. Lo K.W., To K.F., Huang D.P. Focus on nasopharyngeal carcinoma. Cancer Cell 2004, 5:423-428.
3. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 2005, 55:74-108.
4. Chou J., Lin Y.C., Kim J., You L., Xu Z., He B., Jablons D.M. Nasopharyngeal carcinoma - review of the molecular mechanisms of tumorigenesis. Head Neck 2008, 30:946-963.
5. Marks J.E., Phillips J.L., Menck H.R. The national cancer data base report on the relationship of race and national origin to the histology of nasopharyngeal carcinoma. Cancer 1998, 83:582-588.
6. Kwok S.F., Solano R., Tsuge T., Chamovitz D.A., Ecker J.R., Matsui M., Deng X.W. Arabidopsis homologs of a c-Jun coactivator are present both in monomeric form and in the COP9 complex, and their abundance is differentially affected by the pleiotropic cop/det/fus mutations. Plant Cell 1998, 10:1779-1790.
7. Chan A.S., To K.F., Lo K.W., Mak K.F., Pak W., Chiu B., Tse G.M., Ding M., Li X., Lee J.C., Huang D.P. High frequency of chromosome 3p deletion in histologically normal nasopharyngeal epithelia from southern Chinese. Cancer Res. 2000, 60:5365-5370.
8. Chan A.S., To K.F., Lo K.W., Ding M., Li X., Johnson P., Huang D.P. Frequent chromosome 9p losses in histologically normal nasopharyngeal epithelia from southern Chinese. Int. J. Cancer 2002, 102:300-303.
9. Tsang C.M., Zhang G., Seto E., Takada K., Deng W., Yip Y.L., Man C., Hau P.M., Chen H., Cao Y., Lo K.W., Middeldorp J.M., Cheung A.L., Tsao S.W. Epstein-barr virus infection in immortalized nasopharyngeal epithelial cells: regulation of infection and phenotypic characterization. Int. J. Cancer. J. Int. du Cancer 2010, 127:1570-1583.
10. Al-Sarraf M., LeBlanc M., Giri P.G., Fu K.K., Cooper J., Vuong T., Forastiere A.A., Adams G., Sakr W.A., Schuller D.E., Ensley J.F. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized intergroup study 0099. J. Clin. Oncol. 1998, 16:1310-1317.
11. Cheng S.H., Jian J.J., Tsai S.Y., Yen K.L., Chu N.M., Chan K.Y., Tan T.D., Cheng J.C., Leu S.Y., Hsieh C.Y., Huang A.T. Long-term survival of nasopharyngeal carcinoma following concomitant radiotherapy and chemotherapy. Int. J. Radiat. Oncol. Biol. Phys. 2000, 48:1323-1330.
12. Pan Y., Zhang Q., Tian L., Wang X., Fan X., Zhang H., Claret F.X., Yang H. Jab1/CSN5 negatively regulates p27 and plays a role in the pathogenesis of nasopharyngeal carcinoma. Cancer Res. 2012, 72:1890-1900.
13. Pan Y., Zhang Q., Atsaves V., Yang H., Claret F.X. Suppression of Jab1/CSN5 induces radio- and chemo-sensitivity in nasopharyngeal carcinoma through changes to the DNA damage and repair pathways. Oncogene 2012, [Epub ahead of print] PMID:22797071. 10.1038/onc.2012.294.
14. Chamovitz D.A., Wei N., Osterlund M.T., von Arnim A.G., Staub J.M., Matsui M., Deng X.W. The COP9 complex, a novel multisubunit nuclear regulator involved in light control of a plant developmental switch. Cell 1996, 86:115-121.
15. Karniol B., Chamovitz D.A. The COP9 signalosome: from light signaling to general developmental regulation and back. Curr. Opin. Plant Biol. 2000, 3:387-393.
16. Chamovitz D.A., Segal D. JAB1/CSN5 and the COP9 signalosome. A complex situation. EMBO Rep. 2001, 2:96-101.
17. Claret F.X., Hibi M., Dhut S., Toda T., Karin M. A new group of conserved coactivators that increase the specificity of AP-1 transcription factors. Nature 1996, 383:453-457.
18. Wei N., Deng X.W. The COP9 signalosome. Annu. Rev. Cell Dev. Biol. 2003, 19:261-286.
19. Tomoda K., Kubota Y., Arata Y., Mori S., Maeda M., Tanaka T., Yoshida M., Yoneda-Kato N., Kato J.Y. The cytoplasmic shuttling and subsequent degradation of p27Kip1 mediated by Jab1/CSN5 and the COP9 signalosome complex. J. Biol. Chem. 2002, 277:2302-2310.
20. Bounpheng M.A., Melnikova I.N., Dodds S.G., Chen H., Copeland N.G., Gilbert D.J., Jenkins N.A., Christy B.A. Characterization of the mouse JAB1 cDNA and protein. Gene 2000, 242:41-50.
21. Maytal-Kivity V., Piran R., Pick E., Hofmann K., Glickman M.H. COP9 signalosome components play a role in the mating pheromone response of S. cerevisiae. EMBO Rep. 2002, 3:1215-1221.
22. Shackleford T.J., Claret F.X. JAB1/CSN5: a new player in cell cycle control and cancer. Cell Div. 2010, 5:26.
23. Kouvaraki M.A., Korapati A.L., Rassidakis G.Z., Tian L., Zhang Q., Chiao P., Ho L., Evans D.B., Claret F.X. Potential role of Jun activation domain-binding protein 1 as a negative regulator of p27kip1 in pancreatic adenocarcinoma. Cancer Res. 2006, 66:8581-8589.
24. Tomoda K., Kubota Y., Kato J. Degradation of the cyclin-dependent-kinase inhibitor p27Kip1 is instigated by Jab1. Nature 1999, 398:160-165.
25. Oh W., Lee E.W., Sung Y.H., Yang M.R., Ghim J., Lee H.W., Song J. Jab1 induces the cytoplasmic localization and degradation of p53 in coordination with Hdm2. J. Biol. Chem. 2006, 281:17457-17465.
26. Doronkin S., Djagaeva I., Beckendorf S.K. CSN5/Jab1 mutations affect axis formation in the Drosophila oocyte by activating a meiotic checkpoint. Development 2002, 129:5053-5064.
27. Wan M., Cao X., Wu Y., Bai S., Wu L., Shi X., Wang N. Jab1 antagonizes TGF-beta signaling by inducing Smad4 degradation. EMBO Rep. 2002, 3:171-176.
28. Kim B.C., Lee H.J., Park S.H., Lee S.R., Karpova T.S., McNally J.G., Felici A., Lee D.K., Kim S.J. Jab1/CSN5, a component of the COP9 signalosome, regulates transforming growth factor beta signaling by binding to Smad7 and promoting its degradation. Mol. Cell. Biol. 2004, 24:2251-2262.
29. Li S., Liu X., Ascoli M. P38JAB1 binds to the intracellular precursor of the lutropin/choriogonadotropin receptor and promotes its degradation. J. Biol. Chem. 2000, 275:13386-13393.
30. Huang Y.T., Iwamoto K., Kurosaki T., Nasu M., Ueda S. The neuronal POU transcription factor Brn-2 interacts with Jab1, a gene involved in the onset of neurodegenerative diseases. Neurosci. Lett. 2005, 382:175-178.
31. Korbonits M., Chahal H.S., Kaltsas G., Jordan S., Urmanova Y., Khalimova Z., Harris P.E., Farrell W.E., Claret F.X., Grossman A.B. Expression of phosphorylated p27(Kip1) protein and Jun activation domain-binding protein 1 in human pituitary tumors. J. Clin. Endocrinol. Metab. 2002, 87:2635-2643.
32. Fukumoto A., Ikeda N., Sho M., Tomoda K., Kanehiro H., Hisanaga M., Tsurui Y., Tsutsumi M., Kato J.Y., Nakajima Y. Prognostic significance of localized p27Kip1 and potential role of Jab1/CSN5 in pancreatic cancer. Oncol. Rep. 2004, 11:277-284.
33. Kouvaraki M.A., Rassidakis G.Z., Tian L., Kumar R., Kittas C., Claret F.X. Jun activation domain-binding protein 1 expression in breast cancer inversely correlates with the cell cycle inhibitor p27(Kip1). Cancer Res. 2003, 63:2977-2981.
34. Esteva F.J., Sahin A.A., Rassidakis G.Z., Yuan L.X., Smith T.L., Yang Y., Gilcrease M.Z., Cristofanilli M., Nahta R., Pusztai L., Claret F.X. Jun activation domain binding protein 1 expression is associated with low p27(Kip1)levels in node-negative breast cancer. Clin. Cancer Res. 2003, 9:5652-5659.
35. Osoegawa A., Yoshino I., Kometani T., Yamaguchi M., Kameyama T., Yohena T., Maehara Y. Overexpression of Jun activation domain-binding protein 1 in nonsmall cell lung cancer and its significance in p27 expression and clinical features. Cancer 2006, 107:154-161.
36. Goto A., Niki T., Moriyama S., Funata N., Moriyama H., Nishimura Y., Tsuchida R., Kato J.Y., Fukayama M. Immunohistochemical study of Skp2 and Jab1, two key molecules in the degradation of P27, in lung adenocarcinoma. Pathol. Int. 2004, 54:675-681.
37. Dong Y., Sui L., Watanabe Y., Yamaguchi F., Hatano N., Tokuda M. Prognostic significance of Jab1 expression in laryngeal squamous cell carcinomas. Clin. Cancer Res. 2005, 11:259-266.
38. Hsu M.C., Huang C.C., Chang H.C., Hu T.H., Hung W.C. Overexpression of Jab1 in hepatocellular carcinoma and its inhibition by peroxisome proliferator-activated receptor{gamma} ligands in vitro and in vivo. Clin. Cancer Res. 2008, 14:4045-4052.
39. Ahn J., Hong S.A., Lee S.E., Kim J., Oh Y.S., Park S.J., Chung Y.J. Cytoplasmic localization of Jab1 and p27 Kip1 might be associated with invasiveness of papillary thyroid carcinoma. Endocr. J. 2009, 56:707-713.
40. Shintani S., Li C., Mihara M., Hino S., Nakashiro K., Hamakawa H. Skp2 and Jab1 expression are associated with inverse expression of p27(KIP1) and poor prognosis in oral squamous cell carcinomas. Oncology 2003, 65:355-362.
41. Supriatno K., Harada H.Yoshida., Sato M. Basic investigation on the development of molecular targeting therapy against cyclin-dependent kinase inhibitor p27Kip1 in head and neck cancer cells. Int. J. Oncol. 2005, 27:627-635.
42. Rassidakis G.Z., Claret F.X., Lai R., Zhang Q., Sarris A.H., McDonnell T.J., Medeiros L.J. Expression of p27(Kip1) and c-Jun activation binding protein 1 are inversely correlated in systemic anaplastic large cell lymphoma. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 2003, 9:1121-1128.
43. Sui L., Dong Y., Ohno M., Watanabe Y., Sugimoto K., Tai Y., Tokuda M. Jab1 expression is associated with inverse expression of p27(kip1) and poor prognosis in epithelial ovarian tumors. Clin. Cancer Res. 2001, 7:4130-4135.
44. Shackleford T.J., Zhang Q., Tian L., Vu T.T., Korapati A.L., Baumgartner A.M., Le X.F., Liao W.S., Claret F.X. Stat3 and CCAAT/enhancer binding protein beta (C/EBP-beta) regulate Jab1/CSN5 expression in mammary carcinoma cells. Breast Cancer Res. 2011, 13:R65.
45. Chen H., Hutt-Fletcher L., Cao L., Hayward S.D. A positive autoregulatory loop of LMP1 expression and STAT activation in epithelial cells latently infected with Epstein-barr virus. J. Virol. 2003, 77:4139-4148.
46. Wang F., Wang Y., Yu X., Yang D., Wang Z., Lu C., Yuan Z., Xiao M., Shen A. Significance of Jab1 expression in human esophageal squamous cell carcinoma. J. Clin. Gastroenterol. 2009, 43:520-526.
47. Dong Y., Sui L., Watanabe Y., Yamaguchi F., Hatano N., Tokuda M. Prognostic significance of Jab1 expression in laryngeal squamous cell carcinomas. Clin. Cancer Res. 2005, 11:259-266.
48. Hsu M.C., Chang H.C., Hung W.C. HER-2/neu transcriptionally activates Jab1 expression via the AKT/beta-catenin pathway in breast cancer cells. Endocr. Relat. Cancer 2007, 14:655-667.
49. Tian L., Peng G., Parant J.M., Leventaki V., Drakos E., Zhang Q., Parker-Thornburg J., Shackleford T.J., Dai H., Lin S.Y., Lozano G., Rassidakis G.Z., Claret F.X. Essential roles of Jab1 in cell survival, spontaneous DNA damage and DNA repair. Oncogene 2010, 29:6125-6137.
50. Tomoda K., Yoneda-Kato N., Fukumoto A., Yamanaka S., Kato J.Y. Multiple functions of Jab1 are required for early embryonic development and growth potential in mice. J. Biol. Chem. 2004, 279:43013-43018.
51. Wang Z., Fukushima H., Inuzuka H., Wan L., Liu P., Gao D., Sarkar F.H., Wei W. Skp2 is a promising therapeutic target in breast cancer. Oncology 2012, 1.
52. Cocklin R., Goebl M. Nutrient sensing kinases PKA and Sch9 phosphorylate the catalytic domain of the ubiquitin-conjugating enzyme Cdc34. PLoS ONE 2011, 6:e27099.
53. Doronkin S., Djagaeva I., Beckendorf S.K. The COP9 signalosome promotes degradation of Cyclin E during early Drosophila oogenesis. Dev. Cell 2003, 4:699-710.
54. Yoshida A., Yoneda-Kato N., Panattoni M., Pardi R., Kato J.Y. CSN5/Jab1 controls multiple events in the mammalian cell cycle. FEBS Lett. 2010, 584:4545-4552.
55. Fukumoto A., Tomoda K., Yoneda-Kato N., Nakajima Y., Kato J.Y. Depletion of Jab1 inhibits proliferation of pancreatic cancer cell lines. FEBS Lett. 2006, 580:5836-5844.
56. Sitte S., Glasner J., Jellusova J., Weisel F., Panattoni M., Pardi R., Gessner A. JAB1 is essential for B cell development and germinal center formation and inversely regulates Fas ligand and Bcl6 expression. J. Immunol. 2012, 188:2677-2686.
57. Wang H., Song W., Hu T., Zhang N., Miao S., Zong S., Wang L. Fank1 interacts with Jab1 and regulates cell apoptosis via the AP-1 pathway. Cell. Mol. Life Sci. 2011, 68:2129-2139.
58. Liu X., Pan Z., Zhang L., Sun Q., Wan J., Tian C., Xing G., Yang J., Jiang J., He F. JAB1 accelerates mitochondrial apoptosis by interaction with proapoptotic BclGs. Cell. Signal. 2008, 20:230-240.
59. Lu H., Liang X., Issaenko O.A., Hallstrom T.C. Jab1/CSN5 mediates E2F dependent expression of mitotic and apoptotic but not DNA replication targets. Cell Cycle 2011, 10:3317-3326.
60. Liu R.Y., Dong Z., Liu J., Yin J.Y., Zhou L., Wu X., Yang Y., Mo W., Huang W., Khoo S.K., Chen J., Petillo D., Teh B.T., Qian C.N., Zhang J.T. Role of eIF3a in regulating cisplatin sensitivity and in translational control of nucleotide excision repair of nasopharyngeal carcinoma. Oncogene 2011, 30:4814-4823.
61. Wang Z., Li Y., Ahmad A., Banerjee S., Azmi A.S., Kong D., Sarkar F.H. Pancreatic cancer: understanding and overcoming chemoresistance. Nat. Rev. 2011, 8:27-33.
62. Khanna K.K., Jackson S.P. DNA double-strand breaks: signaling, repair and the cancer connection. Nat. Genet. 2001, 27:247-254.
63. van Gent D.C., Hoeijmakers J.H., Kanaar R. Chromosomal stability and the DNA double-stranded break connection. Nat. Rev. 2001, 2:196-206.
64. Shinohara A., Ogawa H., Ogawa T. Rad51 protein involved in repair and recombination in S. cerevisiae is a RecA-like protein. Cell 1992, 69:457-470.
65. Walker J.R., Corpina R.A., Goldberg J. Structure of the Ku heterodimer bound to DNA and its implications for double-strand break repair. Nature 2001, 412:607-614.
66. Buscemi G., Perego P., Carenini N., Nakanishi M., Chessa L., Chen J., Khanna K., Delia D. Activation of ATM and Chk2 kinases in relation to the amount of DNA strand breaks. Oncogene 2004, 23:7691-7700.
67. Rogakou E.P., Pilch D.R., Orr A.H., Ivanova V.S., Bonner W.M. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J. Biol. Chem. 1998, 273:5858-5868.
68. Wang J., Barnes R.O., West N.R., Olson M., Chu J.E., Watson P.H. Jab1 is a target of EGFR signaling in ERalpha-negative breast cancer. Breast Cancer Res. 2008, 10:R51.
69. Kleemann R., Hausser A., Geiger G., Mischke R., Burger-Kentischer A., Flieger O., Johannes F.J., Roger T., Calandra T., Kapurniotu A., Grell M., Finkelmeier D., Brunner H., Bernhagen J. Intracellular action of the cytokine MIF to modulate AP-1 activity and the cell cycle through Jab1. Nature 2000, 408:211-216.
70. Nemajerova A., Mena P., Fingerle-Rowson G., Moll U.M., Petrenko O. Impaired DNA damage checkpoint response in MIF-deficient mice. EMBO J. 2007, 26:987-997.